Pfizer stock hits 52-week high after FDA approves Tukysa regimen

Pfizer shares hit a new 52-week high of $29.88, clearing the previous peak of $29.21. FDA approved Tukysa regimen for HER2-positive breast cancer on October 7, 2026. Phase 3 trial showed 35.9% lower risk of disease progression or death vs placebo. Median progression-free survival extended by 8.6 months (24.9 vs 16.3 months). Healthcare sector rallied broadly with Eli Lilly up 5% and Zoetis up 4.7%.

Pfizer TUKYSA regimen gets FDA approval for HER2+ breast cancer

FDA approves TUKYSA combination for frontline maintenance in HER2+ metastatic breast cancer. Median progression-free survival improved by 8.6 months to 24.9 months vs 16.3 months. Study showed 35.9% reduction in risk of disease progression or death. Hepatotoxicity led to treatment discontinuation in 8% of patients.

Florida AG sues Pfizer for misleading COVID-19 vaccine safety claims

Florida AG sues Pfizer and CEO Albert Bourla for deceptive trade practices. Complaint alleges concealment of safety risks including myocarditis and strokes. Pfizer spent >$10 billion on ads generating >$80 billion in vaccine sales. CEO Bourla earned ~$102 million in compensation during the 2020-2023 period.

Pfizer LITFULO shows significant vitiligo repigmentation in Phase 3

Pfizer's LITFULO significantly improved facial and total body repigmentation in nonsegmental vitiligo patients compared to placebo in two Phase 3 trials. In the high-dose group, 21.86% achieved F-VASI75 versus 2.40% for placebo, while 13.02% reached T-VASI50 versus 2.40%. The safety profile remained consistent with established data for alopecia areata, with no new safety signals observed. Pfizer plans to submit these data to global regulatory authorities, including the US FDA and European Medicines Agency.

Pfizer tilrekimig meets Phase 2 endpoint in atopic dermatitis

Tilrekimig met primary endpoint in Phase 2 atopic dermatitis trial. EASI-75 response reached 62.5% in Stage 1 vs 19.9% placebo. Monthly dosing showed 47.8%-61.0% EASI-75 response vs 9.1% placebo. Itch reduction improved by up to 43.6% in exploratory analysis.

Pfizer to present 45 oncology abstracts at ESMO Congress in Madrid

Pfizer presents 45 abstracts, including 11 oral sessions, at ESMO 2026 in Madrid. Late-stage pipeline candidates atirmociclib and tivunatamig feature in key presentations. New data supports PADCEV and TALZENNA as standards of care in urothelial and prostate cancers. Patient-reported outcomes from TALAPRO-3 study highlight focus on quality of life.